Loading
In a small trial combining PD-L1 and VEGF blockade, four in ten patients with previously treated peritoneal mesothelioma responded, with responses lasting well over a year, the first dedicated prospective evidence for immunotherapy in this rare disease.
Single-centre phase 2 study of 20 patients with advanced unresectable peritoneal mesothelioma progressing after platinum-pemetrexed, treated with atezolizumab and bevacizumab.
Objective response was 40 percent with a median duration of response of 12.8 months, one-year progression-free survival 61 percent and one-year overall survival 85 percent; biomarker analyses linked response to epithelial-mesenchymal transition and immune features.
Immunotherapy combinations, largely extrapolated from pleural trials, now have direct supporting data in peritoneal mesothelioma and are used after or instead of chemotherapy in unresectable disease.
Shares Atezolizumab, Bevacizumab.
Shares Atezolizumab, Bevacizumab.
Shares Atezolizumab, Bevacizumab.
Shares Atezolizumab, Bevacizumab.
Shares Atezolizumab, Bevacizumab.
Shares Atezolizumab, Bevacizumab.
Shares Atezolizumab, Bevacizumab.
Shares Atezolizumab, Bevacizumab.